Compare ALRS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALRS | KALV |
|---|---|---|
| Founded | 1879 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.0M | 551.2M |
| IPO Year | 2019 | N/A |
| Metric | ALRS | KALV |
|---|---|---|
| Price | $25.25 | $14.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $25.40 | ★ $30.00 |
| AVG Volume (30 Days) | 153.7K | ★ 759.3K |
| Earning Date | 01-28-2026 | 03-11-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $223,819,000.00 | $1,426,000.00 |
| Revenue This Year | $38.69 | N/A |
| Revenue Next Year | $4.71 | $204.16 |
| P/E Ratio | $37.13 | ★ N/A |
| Revenue Growth | ★ 9.80 | N/A |
| 52 Week Low | $15.78 | $8.99 |
| 52 Week High | $26.32 | $19.00 |
| Indicator | ALRS | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 46.56 |
| Support Level | $24.65 | $14.41 |
| Resistance Level | $26.00 | $16.59 |
| Average True Range (ATR) | 0.68 | 0.83 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 62.72 | 26.96 |
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and Mortgage. It provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services as well as wealth management services, including financial & estate planning, trust, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.